Skip to main content
SAM CHUN DANG PHARM CO. LTD logo

SAM CHUN DANG PHARM CO. LTD — Investor Relations & Filings

Ticker · 000250 ISIN · KR7000250001 KO Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2026-03-20 Regulatory Filings
Country KR South Korea
Listing KO 000250

About SAM CHUN DANG PHARM CO. LTD

http://www.scd.co.kr/english/scd/index.…

SAM CHUN DANG PHARM CO. LTD. is a pharmaceutical company focused on the development, manufacturing, and sale of medications. The company specializes in ophthalmic products, establishing itself as a significant player in the generic eye care market. Its portfolio also extends to other therapeutic areas, including antibiotics and medications for the circulatory system. The company produces a range of ethical (prescription) and over-the-counter (OTC) drugs in both sterile and non-sterile forms. Manufacturing operations adhere to international quality standards, holding both US and EU Good Manufacturing Practice (GMP) certifications.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding an upcoming Investor Relations (IR) event, specifically a Non-deal Roadshow (NDR) scheduled for April 2026. It outlines the date, location, purpose, and key topics to be discussed with investors. Since this is an announcement of an investor presentation event rather than the presentation slides themselves, and it fits the criteria for a regulatory filing regarding corporate events, it is classified as an Investor Presentation announcement or general regulatory filing. Given the specific nature of the IR event announcement, it falls under the RNS category as a general regulatory announcement for corporate events.
2026-03-20 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (제1형 당뇨병 환자를 대상으로 정상혈당 클램프 조건 및 식이 섭취 후, 경구용 인슐린 SCD0503과 피하 투여 인슐린 간의 상대적 생체이용률, 상대적 생물학적 효력 및 음식 영향 평가를 위한 임상시험)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Samchundang Pharm regarding the submission of a clinical trial application (Phase 1/2) for an oral insulin product. It is a formal disclosure of a material management event (major management matter) related to clinical trial progress. Since it does not fit into specific categories like financial reports, dividends, or share transactions, and is a formal regulatory disclosure of a business event, it is classified as a Regulatory Filing (RNS).
2026-03-19 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Samchundang Pharm Co., Ltd. It contains the meeting date, location, agenda items (financial statement approval, director/auditor appointments, etc.), and detailed management information including board activity and financial statements. This document is a standard proxy statement/notice for an upcoming shareholder meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2026-03-10 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Samchundang Pharm. It details the date, location, and agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors and auditors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI).
2026-03-03 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted by Samchundang Pharm regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for choosing this date despite regulatory recommendations to avoid it. Since this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a report publication announcement, it falls under the general regulatory filing category.
2026-03-03 Korean
투자판단관련주요경영사항 (경구용 당뇨 치료제 리벨서스 제네릭 및 경구용 비만 치료제 위고비 오럴 제네릭(세마글루타이드) 영국 외 유럽 10개 국가 독점 라이센스 및 상업화 계약 체결)
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Samchundang Pharm regarding a major business decision: the signing of an exclusive licensing and commercialization agreement for pharmaceutical products (Rybelsus and Wegovy generics) in Europe. This type of disclosure, which details a specific business contract, partnership, or material event, is classified as a general regulatory filing (RNS) in the absence of a more specific category like M&A or capital change.
2026-02-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.